6533b856fe1ef96bd12b265d
RESEARCH PRODUCT
The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells
Walburgis BrennerMarco Johannes BattistaAmelie LoeweAnne-sophie HeimesR SchwabAnnette HasenburgSlavomir KrajnakMarcus Schmidtsubject
Cancer ResearchCell Survivalmedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsPharmacologyVinorelbinechemistry.chemical_compoundBreast cancerMafosfamideCell Line TumormedicineHumansInsulinCytotoxic T cellViability assayCyclophosphamidebusiness.industryInsulinVinorelbineGeneral Medicinemedicine.diseaseMetronomic ChemotherapyOncologychemistryAdministration MetronomicFemalebusinessmedicine.drugHormonedescription
Background/aim Breast cancer (BC) may be affected by diabetes and anti-diabetic medication, as well as its therapeutic agents. Low-dose metronomic chemotherapy (LDMC) is an available treatment option in BC. We investigated the impact of insulin on low-dose metronomic vinorelbine and mafosfamide in BC cell lines. Materials and methods Human BC cell lines T-47D, MCF-7, MDA-MB-231, BT-549 and non-tumorigenic breast cell line MCF-10A were exposed to 0.01 μg/ml and 10 μg/ml insulin in combination with low-dose metronomic vinorelbine or mafosfamide. The cell viability was determined after 24-72 hours using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Results Insulin, especially at a concentration of 10 μg/ml, seemed to increase viability of vinorelbine-treated hormone receptor-positive BC cells, whereas low-dose mafosfamide treatment tended to be potentiated by insulin in triple-negative cells. Conclusion Our findings suggest that insulin may influence the cytotoxic activity of LDMC depending on insulin concentration, type of cytotoxic drug used and BC cell line.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-23 | Anticancer Research |